Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

350 results about "Lymph Cell" patented technology

Lym·pho·cyte. A white blood cell formed in bone marrow and distributed throughout the body in lymphatic tissue (for example, lymph nodes, spleen, thymus, tonsils, Peyer patches), where it undergoes proliferation. In normal adults, lymphocytes make up 22-28% of the total number of leukocytes in the circulating blood.

Pathology image cell segmentation method based on U-Net model

The invention relates to a pathological image cell segmentation method based on a U-Net model, and belongs to the field of deep learning and medical image segmentation. According to the method, an improved U-Net model is adopted, and in the preprocessing stage, original point mark data is converted into a continuous density map. A multi-scale attention module is added in a decoder stage of the network. The module effectively combines multi-scale feature fusion and a soft attention mechanism, global and local features in an image can be comprehensively captured, and the expression capability of key cell features is remarkably enhanced, so that the cell segmentation precision is improved. Besides, a pixel channel fusion module is added between layers of the decoder, and the module further enhances the detail recognition capability of the model by integrating local information and pixel-level attention into a channel attention mechanism. According to the method, the Ki-67 positive cells, the Ki-67 negative cells and the tumor infiltrating lymphocytes in the IHC-dyed pathological image can be effectively segmented.
Owner:KUNMING UNIV OF SCI & TECH

Anti-BCMA single-domain antibody, and preparation method therefor and use thereof

Provided are an anti-BCMA single-domain antibody, and a preparation method therefor and the use thereof. Specifically, provided is a single-domain antibody having an amino acid sequence of SEQ ID No. 1. The single-domain antibody has high affinity, can thoroughly specifically target BCMA-positive cells, and can be applied to the detection of BCMA expression in bone marrow cells of MM patients. The single-domain antibody can be prepared into a specific antibody drug clinically used for preventing and treating BCMA-target-related diseases (such as multiple myeloma, B-cell acute lymphoblastic leukemia, non-Hodgkin's lymphoma and Hodgkin's lymphoma); or a BCMA protein detection kit, etc. The single-domain antibody has a stable structure, a small molecular size, is easily recombinantly expressed and has a low production cost, can be used alone or as a drug delivery system to carry relevant drugs, and has very wide prospects and important significance in fields such as drug application and clinical diagnosis.
Owner:CARBIOGENE THERAPEUTICS CO LTD

Expansion of tumor infiltrating lymphocytes (TILS) with tumor necrosis factor receptor superfamily (tnfrsf) agonists and therapeutic combinations of tils and tnfrsf agonists

Methods of expanding tumor infiltrating lymphocytes (TILs) using a tumor necrosis factor receptor superfamily (TNFRSF) agonist, such as a 4-1BB agonist, a CD27 agonist, a glucocorticoid-induced TNF receptor-related agonist, an OX40 agonist, a HVEM agonist, or a CD95 agonist, and uses of such expanded TILs in the treatment of diseases such as cancer are disclosed herein. In addition, in some embodiments, therapeutic combinations of TILs and TNFRSF agonists useful in the treatment of diseases such as cancer, including compositions, uses, and dosing regimens thereof, are disclosed herein.
Owner:IOVANCE BIOTHERAPEUTICS INC

Expansion of TILs utilizing AKT pathways inhibitors

ActiveUS12343380B2Peptide/protein ingredientsAntibody ingredientsTumor infiltrating lymphocyte therapyOncology
In some embodiments, methods of expanding tumor infiltrating lymphocytes using AKT pathway inhibitors and methods of using the expanded tumor infiltrating lymphocytes in the treatment of human diseases, including cancers, are disclosed.
Owner:IOVANCE BIOTHERAPEUTICS INC

Aurone compound and medical application thereof

The invention provides an aurone compound and medical application thereof, and relates to an aurone compound and application thereof in preparation of drugs for preventing and treating myelosuppression or blood system diseases. The aurone compound provided by the invention can significantly improve the myelosuppression state caused by rusotinib and radiotherapy, can recover the generation of erythrocytes after mouse irradiation and use of rusotinib, and has a significant effect on the recovery of leukocytes, especially neutrophils and lymphocytes, of the irradiated mouse. The invention provides a new potential drug for treatment of myelosuppression or blood system diseases.
Owner:ZHEJIANG UNIV +1

Application of Lactobacillus paracasei IOB413 and metagen thereof in improvement of radioactive hematopoietic injury

The invention provides application of lactobacillus paracasei IOB413 and a metagen thereof in preparation of a medicine for improving radioactive hematopoietic injury, and relates to the field of microorganisms. The lactobacillus paracasei IOB413 is preserved in the China General Microbiological Culture Collection Center on June 29, 2018, and the preservation number of the lactobacillus paracasei IOB413 is CGMCC (China General Microbiological Culture Collection Center) No.16022. The lactobacillus paracasei IOB413 has the advantages that the lactobacillus paracasei IOB413 is preserved in the China General Microbiological Culture Collection Center; the lactobacillus paracasei IOB413 and the metaplasm thereof can improve the damage condition of immune organs, increase the number of lymphocytes, increase the number of red blood cells and blood platelets and recover the immune function and hematopoietic function of the organism, so that the radioactive hematopoietic damage is improved.
Owner:TIANJIN INNOORIGIN BIOLOGICAL TECH CO LTD

Chimeric cytokine receptor for activating lymphocytes by using soluble immunosuppressive molecules and application of chimeric cytokine receptor in tumor treatment

The invention relates to the field of biological medicines, in particular to a chimeric cytokine activated receptor for activating lymphocytes by using soluble immunosuppressive molecules and application of the chimeric cytokine activated receptor in tumor treatment. The chimeric cytokine activation receptor and a chimeric antigen receptor for recognizing tumor antigens are connected in parallel to form a co-expressed polycistron structure. Wherein the chimeric cytokine activation receptor comprises an scFv structural domain, a transmembrane structural domain and a cytokine chimeric activation structural domain which specifically recognize and bind soluble immunosuppressive molecules. The CAR-NK cell can specifically recognize soluble inhibitory factors in the tumor microenvironment and improve the in-vivo and in-vitro anti-tumor efficacy of the CAR-NK cell, and can be used for treating solid malignant tumors.
Owner:THE NAVAL MEDICAL UNIV OF PLA

PD1-targeted novel il-2 vitokine fusions

The present disclosure provides a PD1 targeted novel IL-2 VitoKine composition, featuring a high-affinity PD1 antibody domain and a bio-activable IL- 2 domain with optimally reduced potency. The PD1 Ab-IL2 VitoKine platform mitigates IL-2 therapy-related toxicities and synergizes the anti-tumor effects of PD1 and IL- 2 by: 1) efficiently targeting an inert IL-2 directly to tumor-infiltrating lymphocytes (TILs); 2) ensuring highly tumorspecific activation of the IL- 2 domain by TME- enriched proteases that co-localized with TILs; 3) allowing PD1 Ab and activated IL- 2 to act on intratumoral CD8+T cells in cis. The VitoKine demonstrates greatly enhanced concealment efficiency and has a lower intrinsic basal activity than what would typically be expected from the VitoKine platform incorporating a non-attenuated IL-2. This improvement permits a substantially higher dose tolerance, enabling safe administration at efficacious dose levels of the PD1 antibody, reversing T- cell anergy or exhaustion and further synergizing with IL-2 mediated anticancer immune response.
Owner:CUGENE INC

Effect of Intestinia butyriproducens bacteria in anti-tumor immunotherapy

The invention discloses an effect of an Intestinia butyriproducens bacterium in anti-tumor immunotherapy, and finds that colonization of the Intestinia butyriproducens bacterium in intestinal tracts can inhibit growth of CT26 mouse subcutaneous transplanted tumors with poor response to the tumor immunotherapy, meanwhile, growth of human colorectal cancer cells is remarkably inhibited, and apoptosis of tumor cells is promoted for the first time. The application of the Intestinia butyriproducens bacterium in the anti-tumor immunotherapy has the advantages that the effect of the intestinia butyriproducens bacterium in the anti-tumor immunotherapy is achieved, and the application of the intestinia butyriproducens bacterium in the anti-tumor immunotherapy in the anti-tumor immunotherapy in the anti-tumor immunotherapy in the anti-tumor immunotherapy is achieved. Meanwhile, after colonization of the strain and combined administration of PD-1 monoclonal antibodies, the proportion of CD8 + T cells in mouse tumor infiltration lymphocytes is increased, the proportion of depleted PD-1 + CD8 + T cells is reduced, and the proportion of CD8 + T cells releasing functional cell factors interferon gamma and granzyme B is also increased, which shows that after colonization of the strain, the curative effect of tumor immunotherapy can be enhanced, and the tumor immunotherapy effect can be enhanced. The immunoregulation capability and the great clinical application value are realized.
Owner:CHINA PHARM UNIV

Genetic marker and / or biomarkers for traumatic brain injury, and ultrasensitive assays for biomarkers of traumatic brain injury

The present invention relates to assays, methods, and kits to assess traumatic brain injury (TBI) in a subject. The present invention also relates to ultrasensitive assays for GFAP, tau, CKBB, IL-1β, IL-2, IL-6, IL-10, IL-22, IP-10, TNFα, TSLP, NFL, and / or NFH.
Owner:MESO SCALE TECH LLC +2

Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy

The present invention provides improved and / or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs. The methods may comprise gene-editing at least a portion of the TILs to enhance their therapeutic efficacy. Such TILs find use in therapeutic treatment regimens.
Owner:IOVANCE BIOTHERAPEUTICS INC

Collection, genome editing, and washing of T-cell lymphocytes

Blood from a blood source is drawn into a fluid flow circuit. A mononuclear cell product is separated from the blood, followed by at least a portion of the mononuclear cell product being conveyed into an electroporation device without disconnecting the blood source from the fluid flow circuit. The electroporation device opens pores in a membrane of at least one of the cells of the mononuclear cell product to allow DNA material (which is added to the mononuclear cell product prior to electroporation) to enter and modify the genome of the cell. At least a portion of the modified mononuclear cell product is returned to the blood source. The mononuclear cell product may be washed prior to being conveyed into the electroporation device. The modified mononuclear cell product may be washed after exiting the electroporation device.
Owner:FENWAL INC

Application of lactobacillus fermentum in preparation of antitumor drugs

The invention relates to the field of biological medicine, in particular to application of fermented lactobacillus mucus in preparation of immune antitumor drugs. A strain of fermented lactobacillus mucus capable of effectively treating tumors is screened and can activate the immune system of the strain, increase the proportion of CD8 + T lymphocytes in spleen tissues, increase the infiltration proportion of leukocytes in tumors and the proportion of CD4 + and CD8 + T lymphocytes in infiltrated immune cells, change the tumor microenvironment and improve the tumor immunity. Therefore, tumor cells are effectively killed, and the effect of tumor immunotherapy is achieved.
Owner:CHINA PHARM UNIV

Computer-implemented method and system for diagnosing diseases that affect morphological characteristics and the cytoplasmic complexity of blood cells

A computer-implemented method for diagnosing diseases that affect the morphological characteristics and the cytoplasmic complexity of blood cells, the method comprising: a) obtaining blood parameters from at least one patient, the blood parameters comprising at least two measured properties of individual cells from full blood analysis, the individual cells comprising leukocytes, the measured properties of the leukocytes comprising the size and granularity of the cytoplasm and the structure of the cell nucleus; b) creating at least one scatter plot, each axis of the scatter plot comprising a different measured property of the individual cells; c) ascertaining at least one cluster in at least one scatter plot, the clusters comprising the subpopulations of leukocytes, the subpopulations comprising monocytes, lymphocytes, basophils, neutrophils and eosinophils; d) combining the property elements of the ascertained clusters to form a 1-dimensional global vector, the arrangement of the property elements in the global vector comprising an arrangement by associated cluster; e) reducing the dimension of the global vector; f) diagnosing at least one disease by means of an ensemble, the ensemble comprising at least one machine learning model and at least one deep learning model, the at least one machine learning model receiving at least one reduced global vector as an input variable and the at least one deep learning model receiving at least one scatter plot image as an input variable; and g) automatically generating a report which comprises at least one result of the diagnosis of at least one disease.
Owner:ROBOTDREAMS GMBH

Gene-edited tumor infiltrating lymphocyte and T cell receptor engineered T cell and application thereof in immunotherapy

The invention discloses a gene-edited tumor infiltrating lymphocyte and a T cell receptor engineered T cell and application thereof in immunotherapy. According to the invention, NR4A1 and / or NR4A2 and / or NR4A3 genes are / is knocked out from tumor infiltrating lymphocytes or T cell receptor engineered T cells, so that the multiplication capacity and the anti-tumor capacity of the tumor infiltrating lymphocytes or T cell receptor engineered T cells are improved.
Owner:BENNU BIOTHERAPEUTICS (SHANGHAI) CO LTD

Processing of tumor infiltrating lymphocytes

The present invention provides methods for isolating and cryopreserving tumor infiltrating lymphocytes (TILs) and producing therapeutic populations of TILs, including methods via use of a kit and a semi-automatic device for aseptic disaggregation, enrichment, and cryopreservation of a resected tumor prior to expansion of the TIL population. The present invention also provides methods for expansion, and / or stabilization of TILs, for instance UTILs, compositions involving the same and methods of treatment involving the same.
Owner:INSTIL BIO INC

Nouritrophoblast-free one-step culture method of tumor infiltrating lymphocytes and application

PendingCN120173875AMammal material medical ingredientsBlood/immune system cellsTumor infiltrating lymphocyte therapyTrophoblastic cell
The invention discloses a trophoblast-free one-step culture method and application of tumor infiltrating lymphocytes, and particularly discloses a one-step amplification method of tumor infiltrating lymphocytes, which comprises the following steps: treating a tumor sample obtained from a subject into tumor segments; the tumor segments are cultured in a culture medium containing a CD3 agonist, a 4-1BB agonist and IL-2, so that an amplified tumor infiltration lymphocyte population is obtained, and the culture medium does not contain trophoblastic cells. Compared with the prior art, the method has the advantages that the required period for amplifying the tumor infiltrating lymphocytes is shorter, the cost is lower, the cell effect function is stronger, and the clinical application range of the tumor infiltrating lymphocyte therapy is widened.
Owner:BENNU BIOTHERAPEUTICS (SHANGHAI) CO LTD

Application of colla corii asini bone-strengthening oral liquid in preventing and / or treating anemia

PendingCN119792413AMetabolism disorderPharmaceutical delivery mechanismUrea nitrogen/CreatinineSerum iron
The invention discloses application of colla corii asini bone-strengthening oral liquid to prevention and / or treatment of anemia, and belongs to the technical field of medicines, and the anemia comprises iron-deficiency anemia, renal anemia and myelosuppression anemia. The colla corii asini bone strengthening oral liquid can increase erythrocyte count, hemoglobin concentration, hematocrit, erythrocyte average hemoglobin amount, erythrocyte average hemoglobin concentration and / or erythrocyte average volume; the serum iron content is increased; a transporter divalent metal transporter and a membrane iron transporter are increased; the intestinal iron absorption is promoted. The composition specifically comprises urea nitrogen and creatinine; related indexes of renal anemia are improved; the immune index of renal anemia can be improved. The percentage of leukocytes and lymphocytes of anemia caused by myelosuppression can be recovered; the hemoglobin content is increased; the number of macrophage colony stimulating factors and / or bone marrow cells in serum is increased; the immunocompetence is improved; the proliferation of lymphoid B cells and macrophages is promoted.
Owner:XINJIANG HUASHIDAN PHARMA

Pathological tissue section dyeing equipment and method

The invention provides pathological tissue section dyeing equipment and method. The method comprises the following steps: dividing a to-be-dyed lymphatic tissue section into a plurality of dyeing partitions according to the structural characteristics of lymphocyte tissues in the to-be-dyed lymphatic tissue section; dyeing agents with different concentrations are applied to different dyeing partitions according to the reference light transmittance of the lymphocyte tissue to obtain color gradient vectors of the lymphocyte tissue slices, light absorption characteristics of the dyeing partitions are measured through a photometer, and dyeing characteristics are determined based on the light absorption characteristics and the color gradient vectors; obtaining a dyeing image after dyeing the lymph tissue section, extracting deep features of the dyeing partitions from the dyeing image, and determining a dyeing loss value when dyeing the dyeing partitions based on the deep features and the dyeing features; and based on the dyeing loss value, carrying out self-adaptive adjustment on the dyeing agent concentration of each dyeing zone. By adopting the scheme provided by the invention, optimal adjustment on the concentration of the coloring agent in the sample dyeing process can be realized based on the characteristic difference of the cell tissues at different parts.
Owner:SHAOYANG UNIV

Biomarker for predicting prognosis condition of sepsis and application

The invention discloses a biomarker for predicting the prognosis condition of sepsis and application, and belongs to the technical field of biology. The biomarkers comprise a ratio of neutrophils to lymphocytes, a ratio of platelets to lymphocytes, a ratio of monocytes to lymphocytes, a ratio of leukocytes to lymphocytes, a system inflammatory response index and a peripheral inflammatory value. According to the method, the ratio of neutrophil to lymphocyte, the ratio of platelet to lymphocyte, the ratio of mononuclear cell to lymphocyte, the ratio of leukocyte to lymphocyte, a systemic inflammatory response index and a peripheral inflammatory value are utilized to carry out accurate prognosis risk stratification on the sepsis patient, and prognosis survival risk prediction is carried out on the sepsis patient; the accuracy and timeliness of prognosis evaluation of sepsis patients are remarkably improved, a reliable guidance basis is provided for clinical decision making, and the method has important clinical application value and popularization significance.
Owner:LONGHUA HOSPITAL SHANGHAI UNIV OF TRADITIONAL CHINESE MEDICINE

Lactobacillus fermentum strain as well as extracellular vesicles and application thereof

The invention discloses a lactobacillus fermentum strain as well as extracellular vesicles and application thereof. The lactobacillus fermentum strain is named as C283, is preserved in the General Microbiological Center of the China Committee for Culture Collection of Microorganisms, and has the microbial preservation number of CGMCC No.30338. The lactobacillus fermentum strain can be used for preparing the lactobacillus fermentum. Researches show that the strain has unique anti-inflammatory and anti-infection dual characteristics, and also has the characteristics of acid resistance, cholate resistance and the like; particularly, the C283 strain can generate extracellular vesicles with very strong immunologic adjuvant activity and immunological enhancement activity, and the C283 strain outer vesicles can directly activate chicken mucous membrane epithelium lymphocytes only through nasal dripping and eye dripping, so that mucous membrane immune response is remarkably enhanced; particularly, the strain exovesicle can be directly used as an efficient mucosal delivery carrier for inactivated viruses or antigens, nucleic acid vaccines or mRNA vaccines, and efficient mucosal immune system delivery of the inactivated vaccines or antigens can be achieved in a mucosal immune mode. The invention provides a new technical means for preparing novel oral vaccines and mucous membrane delivery vaccines.
Owner:HAERBIN GUOSHENG BIOTECHNOLOGY CO LTD

Method for constructing malignant pleuroperitoneal fluid-derived gastric cancer cell organoid model

The invention provides a method for constructing a malignant pleuroperitoneal fluid-derived gastric cancer cell organoid model. The method comprises malignant pleuroperitoneal fluid sample treatment, gastric cancer cell separation and gastric cancer cell organoid culture. Gastric cancer cells and lymphocytes are separated through layer-by-layer treatment of malignant pleuroperitoneal fluid samples, so that the purity of the gastric cancer cells in the gastric cancer cell organ model can be improved, the proportion of immune cells can be reduced, the authenticity and accuracy of the gastric cancer cell organ model can be enhanced, and the heterogeneity and individualized characteristics of gastric cancer patients can be reflected; therefore, the method has important value for clinical drug screening and precise treatment of gastric cancer patients.
Owner:RUIJIN HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE

Application of YTHDF1 in regulation and control of tryptophan metabolism to promote formation of hepatocellular carcinoma immunosuppression microenvironment

The invention discloses a key effect and a targeted intervention strategy of YTHDF1 in regulation and control of a hepatocellular carcinoma immunosuppression microenvironment. In the tumor-associated fibroblasts, YTHDF1 enhances the translation efficiency of OTUD5 mRNA through an m6A dependency mechanism, an up-regulated deubiquitination enzyme OTUD5 is directly combined with a tryptophan metabolic rate-limiting enzyme IDO1, ubiquitination degradation of the tryptophan metabolic rate-limiting enzyme IDO1 is inhibited, tryptophan is further driven to catabolism to generate kynurenine, regulatory T cell differentiation is promoted, and an immunosuppression microenvironment is formed. Spatial transcriptomics shows that YTHDF1 + CAFs and Tregs are significantly co-localized in tumor tissues and have metabolic interaction. Based on artificial intelligence virtual screening, it is found that a natural compound hesperidin can be specifically combined with a YTH structural domain of YTHDF1, an OTUD5-IDO1 signal axis mediated by the natural compound hesperidin is blocked, and the KYN level is remarkably reduced. Animal experiments prove that the tumor inhibition rate of combined treatment of hesperidin and anti-PD-1 is increased by 40% or above compared with that of a single drug group, and synergistic interaction is achieved by inhibiting Tregs infiltration and enhancing the activity of cytotoxic T lymphocytes.
Owner:JIANGSU PROVINCE HOSPITAL (THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY)

System and method for measuring and analyzing minimal residual disease in childhood b-precursor acute lymphoblastic leukemia by multiparameter flow cytometry

The present invention relates to a system and a method for measuring and analyzing minimal residual disease (MRD) in pediatric B-cell precursor acute lymphoblastic leukemia (B-ALL) using multiparameter flow cytometry (MPFC). The invention finds application in clinical diagnostics and hematology-oncology for quantifying MRD in B-ALL patients with high sensitivity and specificity, needed for risk stratification, monitoring treatment response, and informing therapeutic decisions. The system comprises interconnected subsystems including an acquisition subsystem with an MPFC instrument, a control and file generation subsystem, and an analytical subsystem. The analytical subsystem incorporates modules for sequential data reduction, automated data cleaning, automated unsupervised data clustering, and interactive cluster analysis. Key advantages include high MRD detection sensitivity (e.g., 10⁻⁵ or 0.001%) and high specificity, without reliance on reference samples or supervised machine learning models, making it applicable in laboratories with different measuring equipment and using different panels of antibodies for identification of leukemic cells.
Owner:MEDICAL UNIVERSITY - PLOVDIV

Improved tumor infiltrating lymphocyte in-vitro amplification method

The invention provides an improved in-vitro amplification method of tumor infiltrating lymphocytes. Specifically, the method for preparing the tumor infiltrating lymphocyte (TIL) comprises the following steps: (S1) providing a tumor tissue; (S2) carrying out fragmentation treatment on the tumor tissue to obtain tumor fragments; (S3) pre-culturing the tumor fragments by using a starting culture medium to obtain a first culture mixture; (S4) determining the first culture mixture so as to screen out the tumor reactive TIL; (S5) performing multiplication culture on the tumor reactive TIL by using an amplification culture medium to obtain a second culture mixture; and (S6) isolating or recovering tumor infiltrating lymphocytes (TIL) from the second culture mixture. The invention also provides the high-tumor-reactivity TIL prepared by the method and application of the high-tumor-reactivity TIL.
Owner:SHANGHAI INST OF PHARMA IND CO LTD

Compound as well as preparation method and application thereof

The invention relates to a compound. The compound comprises a polysaccharide conjugate, an anti-PD-L1 monoclonal antibody and a PKM2 inhibitor. The compound disclosed by the invention can be accumulated and retained in tumor tissues, so that dendritic cells are effectively stimulated to be mature, an inhibitory immune microenvironment is relieved, and a specific anti-tumor immune response is initiated. The expression of PKM2 can be effectively inhibited, so that glycolysis in tumor tissues is inhibited, and a more favorable environment is provided for infiltrating the tumor tissues with T lymphocytes. The compound disclosed by the invention is expected to enhance the treatment effect of RFA on advanced HCC patients by reprogramming iRFA-induced tumor immunosuppression, and has huge potential in the aspect of improving prognosis of the advanced HCC patients treated by the RFA.
Owner:SOUTHEAST UNIV